Azitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common Stock

Core Viewpoint - Azitra, Inc. has entered into a securities purchase agreement to sell 3,339,300 shares of common stock at $0.2785 per share, aiming to raise approximately $930.0 thousand for working capital and general corporate purposes [1] Group 1: Offering Details - The offering is expected to close on February 5, 2025, subject to customary closing conditions [1] - Maxim Group LLC is acting as the sole placement agent for the offering [2] - The offering is made under an effective shelf registration statement previously filed with the SEC [3] Group 2: Company Overview - Azitra, Inc. is focused on developing innovative therapies for precision dermatology, with its lead product ATR-12 targeting Netherton syndrome, a rare skin disease [5] - ATR-12 is currently in a Phase 1b clinical trial for adult patients, while ATR-04 is being developed for EGFR inhibitor associated rash and has received Fast Track designation from the FDA [5] - The company utilizes a proprietary platform of engineered proteins and a microbial library of approximately 1,500 bacterial strains, enhanced by AI and machine learning technology [5]